A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.

Metabolic Syndrome Clinical Trial

— SMART  

Official title:

Study of Metformin to Reduce Cerebrovascular Dysfunction in South African Patients With HIV and Metabolic syndRome: a Pilot Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05571319
• Other study ID #: M21/10/024
• Secondary ID: R21TW012185-01
• Status: Recruiting
• Phase: Phase 2
• Start date: August 11, 2022
• Est. completion date: June 2024

Study information

• Verified date: July 2023
• Source: University of Stellenbosch
• Contact: Eric Decloedt, MBChB, PhD
• Phone: +2721938
• Email: ericdecloedt[@]sun.ac.za
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus which frequently occur together. Data is emerging suggesting metabolic syndrome causes brain disease by contributing to blood vessel damage and inflammation. People living with HIV (PLWH) are at high risk and the investigators will perform a pilot study of the well-known type 2 diabetes drug metformin to treat this blood vessel damage and inflammation in PLWH.

Description:

Background: Metabolic syndrome (MetS) is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus (T2D) which frequently occur together. The consequences of MetS extend beyond the increased risk of vascular-metabolic disease. Data is emerging suggesting causality between MetS and cerebral small vessel disease. MetS is associated with an increased incidence of vascular dementia and progression from mild cognitive impairment to dementia. MetS cause endothelial dysfunction and low-level inflammation of adipose tissue. MetS-associated endothelial dysfunction is independent of obesity status with an increased number of MetS abnormalities correlating with more endothelial dysfunction. Middle cerebral artery stiffening with impaired blood flow is associated with a higher MetS score.

Enhanced access to effective combination antiretroviral therapy (cART) improved the life expectancy of people living with HIV (PLWH) substantially. Longevity, however, presents unique health challenges, one being the development of non-communicable diseases including MetS. Emerging data from sub-Saharan Africa indicate a higher prevalence of MetS among PLWH compared with their HIV-negative counterparts. The incidence of MetS in PLWH is predicted to increase. Abdominal obesity is reaching alarming proportions in sub-Saharan Africa with the prevalence similar to that of high-income countries. Older antiretroviral regimens are associated with higher treatment-emergent MetS. Given the growing HIV-positive population with MetS, and that both MetS and HIV are chronic inflammatory conditions, there is an urgent need to identify effective and affordable pharmacotherapy that addresses modifiable aspects of vascular disease.

The investigtors hypothesise that metformin is effective in treating endothelial dysfunction and thus ameliorating cerebrovascular function in HIV-positive patients with metabolic syndrome. Metformin has been shown to affect endothelial cells by inhibiting several inflammatory molecules. Pilot clinical trial data support that metformin significantly improves endothelial function, even in short-term treatment. Metformin is a low-cost and well-known drug used for the management of abnormal glucose homeostasis in people with T2D. Metformin is widely available in public service settings and is considered to have a clinical effect beyond glucose lowering. Based on the rationale above, the investigators propose to study metformin in HIV-positive participants with MetS who are virologically suppressed by standard of care cART to receive open-label metformin to assess its effect on cerebrovascular function.

Objective: The investigators propose to address the Specific Aims listed below in HIV-positive participants with metabolic syndrome virologically suppressed on standard of care cART receiving open-label metformin 12 weeks. Aim 1: To obtain preliminary data on the effect of metformin on cerebral vascular reactivity and cerebral blood flow in HIV positive participants with metabolic syndrome. Aim 2: To assess whether metformin associated changes in cerebral vascular reactivity and cerebral blood flow (CBF) are mediated via improvements in endothelial function.

Methods: The investigators will enroll 30 participants in an open-label study of metformin treatment for 12 weeks with a 4-week washout period and a final evaluation. Comprehensive metabolic, laboratory and neuroimaging evaluation will be performed at screening and 12 weeks with selected procedures repeat after the 4 weeks washout period at week 16. Whole body dual-energy X-ray absorptiometry (DEXA) at study entry will be used to assess adipose tissue location.

Outcome: The purpose of this pilot study in PLWH with MetS is to obtain preliminary data on the effect of metformin on cerebrovascular function using non-invasive neuroimaging biomarkers. Furthermore, the investigators will test the hypothesis that metformin mediates the cerebrovascular changes in part via endothelial regulation by using a comprehensive panel of endothelial functional and soluble markers which will be correlated with the imaging metrics. The results of the study will form the basis for a future clinical trial that will assess the beneficial effect of metformin in reducing the burden of cerebral small vessel disease in PLWH.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (>18 years);

• HIV+ on antiretroviral therapy for at least 12 months prior to study entry;

• Viral load =50 copies/mL;

• Able to provide informed consent;

• Metabolic syndrome as per the harmonized criteria;

• Women of child-bearing potential willing to use adequate contraception (defined as either an intra-uterine contraceptive device or hormonal contraceptive);

Exclusion Criteria:

• Treated with metformin as part of care;

• History of drug or alcohol abuse within 3 months before screening;

• Known neurosyphilis;

• Known vitamin B12 deficiency;

• Known neuropsychiatric disorders or serious psychiatric symptoms;

• Significant head trauma with imaging structural abnormalities;

• Renal impairment (estimated glomerular filtration < 60 mL/min/1.73m2);

• Type I or type II diabetes (fasting plasma glucose >7mmol/L and/or HbA1c >6.5%);

• Hypersensitivity to metformin;

• Any contraindication or special precaution in the metformin package insert which may put the participant at a safety risk;

• Cationic drugs (as listed in the metformin package insert) that may increase metformin concentrations significantly;

• Claustrophobia, metal implants or any other condition that prevents performing MR scan;

• Pregnant / breastfeeding;

Related Conditions & MeSH terms

• HIV Seropositivity
• Metabolic Syndrome
• Syndrome

Intervention

Drug:
• Metformin Extended Release Oral Tablet
Glucophage XR 500 mg

Locations

Country	Name	City	State
South Africa	Desmond Tutu Health Foundation: Gugulethu Research Site	Cape Town	Western Cape

Sponsors (3)

Lead Sponsor	Collaborator
University of Stellenbosch	Fogarty International Center of the National Institute of Health, University of Rochester

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Outcome: cerebral reactivity.	We will measure changes in cerebrovascular reactivity (percentage change of BOLD signal during resting state fMRI) from baseline to 12 weeks.	12 weeks
Primary	Outcome: cerebral blood flow.	We will measure changes in cerebral blood flow (mL/100mL/min, via arterial spin labeling) from baseline to 12 weeks.	12 weeks
Primary	Outcome: peripheral vascular reactivity.	We will measure changes in finger reactive hyperemia index from baseline to 12 weeks.	12 weeks